Key Points {#FPar1}
==========

Our meta-analysis of randomized, placebo-controlled trials did not identify any safety issue associated with glucosamine sulfate (GS) or chondroitin sulfate (CS).Diacerein is associated with significantly more adverse events than placebo, particularly regarding the gastrointestinal and renal and urinary systems. The usefulness of diacerein for patients with OA should therefore be considered, taking into account its benefit:risk profile according to individual patient characteristics.Avocado soybean unsaponifiables (ASU) as a whole require further investigation in safety studies without any concomitant anti-OA medication; however, our analyses, which included only the proprietary ASU Piascledine^®^ in studies that allowed concomitant anti-OA medications, seem to support the safety of this product, but this remains to be confirmed.

Introduction {#Sec1}
============

Osteoarthritis (OA) is a progressive disorder of synovial joints of the hand, knee, and hip that causes pain and limitation of function, increasing disability, and progressive cartilage degeneration \[[@CR1]\]. OA occurs frequently in adults aged \> 50 years, with increasing incidence, and is a major cause of disability worldwide \[[@CR1]--[@CR3]\]. There is currently no established disease-modifying therapy for OA, so treatment relies on a combination of pharmacologic and non-pharmacologic therapies that can manage OA symptoms, primarily pain and loss of function \[[@CR4]\]. Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) are an important class in the pharmacologic treatment armamentarium for OA that have been demonstrated to alleviate the symptoms of pain and functional impairment, with some additional evidence of a disease-modifying effect in the long term \[[@CR5]--[@CR7]\]. The SYSADOAs class comprises many different agents, including glucosamine, chondroitin, diacerein, and avocado soybean unsaponifiables (ASU), which are supported by varying degrees of clinical efficacy data. Meta-analyses of placebo-controlled trials of SYSADOAs treatment lasting up to 3 years provide evidence that prescription-grade crystalline glucosamine sulfate (GS), chondroitin sulfate (CS), and diacerein have small to moderate beneficial effects in patients with OA \[[@CR5], [@CR8]--[@CR10]\].

The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) recommends the use of SYSADOAs as step 1 pharmacologic background therapy, specifically prescription-grade GS and CS, with paracetamol as add-on rescue analgesia when needed \[[@CR4]\]. However, the level of recommendation afforded to SYSADOAs by other international and national guidelines is less favorable, likely because of the multiple products available, including over-the-counter medications and nutritional supplements that contain the active ingredients but for which the pharmaceutical quality is considerably reduced \[[@CR11]--[@CR14]\]. Some issues have been raised in the literature regarding several anti-OA preparations that could not be considered clinically equivalent to their SYSADOA counterparts, which could compromise the efficacy and safety of these products \[[@CR15], [@CR16]\].

Despite the controversies and non-concordant recommendations about SYSADOAs, they are widely used in many countries as prescription or over-the-counter medications in patients with OA \[[@CR17], [@CR18]\]. In this context, it is of primary importance to clearly establish their safety profile. In fact, while some SYSADOAs are considered safe for use in patients with OA, some concerns have been raised about the safety profile of other agents. For example, diacerein may induce loose stools or diarrhea as it is incompletely absorbed in the upper gastrointestinal tract \[[@CR19]\].

A Cochrane review found significantly more adverse events (AEs) with diacerein than with placebo after 2--36 months; the AEs were mainly diarrhea (relative risk \[RR\] 3.5; 95% confidence interval \[CI\] 2.42--5.11), with an absolute risk increase of 24% (95% CI 12--35) and a number needed to treat for an additional harmful outcome (NNTH) of 4 (95% CI 3--7) \[[@CR20]\].

The SYSADOAs GS and CS are generally considered safe medications, with no difference in AEs compared with placebo \[[@CR6], [@CR7], [@CR21]\]. Only limited evidence is available on the safety of ASU; however, a meta-analysis of five placebo-controlled trials found no difference in AEs between ASU and placebo \[[@CR22]\].

Notably, the meta-analyses that have assessed the safety of SYSADOAs used only published data, and it is well-known that safety data are under-reported in manuscripts. The objective of this study was to re-assess the safety of SYSADOAs in the management of OA in a systematic review and meta-analysis of randomized placebo-controlled trials (RCTs). To better estimate the safety profile of these OA medications, authors of the manuscripts and/or sponsors of studies were contacted to ask for the full report of AEs.

Methods {#Sec2}
=======

The protocol of this systematic review and meta-analysis was previously registered in the PROSPERO database (registration number: CRD42017069875). The systematic review was performed in accordance with the recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* \[[@CR23]\]. The findings were reported according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines \[[@CR24]\]. The entire review process (study selection and risk-of-bias assessment) was undertaken using Covidence, the Cochrane platform for systematic reviews.

Eligibility Criteria {#Sec3}
--------------------

Randomized, double-blind, placebo-controlled, parallel-group trials that assessed the AEs associated with various SYSADOAs in patients with OA were eligible for inclusion in this meta-analysis. The SYSADOAs considered were limited to GS, CS, hyaluronic acid, collagen derivatives, diacerein, ASU and curcuma, administered orally. The following studies were excluded: crossover studies, reviews or meta-analyses, letters, comments, or editorials. Studies that allowed concomitant anti-OA medications during the trial (other than rescue medication such as paracetamol or aspirin) were also excluded for the main meta-analysis but were kept and used for a parallel analysis.

Data Sources and Search Strategies {#Sec4}
----------------------------------

A comprehensive literature search was undertaken in the databases MEDLINE (via Ovid), Cochrane Central Register of Controlled Trials (Ovid CENTRAL), and Scopus. Each database was searched from inception up until 31 May 2017. We searched for RCTs of various SYSADOAs in OA, using a combination of study design-, treatment-, and disease-specific keywords and/or medical subject heading (MeSH) terms. While AEs were the outcomes of interest for this study, we decided to avoid the outcome-specific keywords in the search strategies because of the possibility that a study on the efficacy of a drug may have not mentioned terms related to AEs in its title, abstract, or keywords. The search was limited to English and French publications and to human subjects. Detailed search strategies for MEDLINE/CENTRAL and Scopus databases are reported in the Electronic Supplementary Material (ESM)-1.

Two clinical trials registries, ClinicalTrials.gov (clinicaltrials.gov/) and the World Health Organization's International Clinical Trials Registry Platform Search portal (apps.who.int/trialsearch/) were also checked for trial results that would not have been published. Finally, very recent meta-analyses were also screened for any additional relevant studies. For all studies that responded to the selection criteria, authors of the manuscripts and/or sponsors of studies were automatically contacted to ask for the full report of AEs, as far as there was any way to contact them (email, fax, telephone number or co-author email in another article).

We set up search alerts in the bibliographic databases for any new relevant RCTs that were published from 31 May 2017 until 30 September 2018.

Study Selection and Data Extraction {#Sec5}
-----------------------------------

Two members of the review team (GH and AG) independently evaluated each title and abstract to exclude only obviously irrelevant studies according to the predefined eligibility criteria. At this step, the criteria related to adverse effects were not considered, as studies focusing on the efficacy of a treatment may not report data about adverse effects in the abstract; this means that all trials mentioning only the efficacy information were retrieved at this step. After this first step, the two investigators (GH and AG) independently reviewed the full text of each of the articles not excluded during the initial screening stage to determine whether the studies met all selection criteria, and those that did not were definitely excluded. All differences of opinion regarding the selection of articles were resolved through discussion and consensus between the two investigators; any persistent disagreement was resolved with the intervention of a third person (VR). A flowchart with the number of included studies at each step was established, including the reasons for excluding studies during the full text reading process.

The full texts of the selected studies were screened for extraction of relevant data using a standard data extraction form. Outcome results data were independently extracted by two investigators of the review team (GH and AG). For each study, the following data were extracted: characteristics of the manuscript, trial, patients, disease, and treatments; study objective and design; AEs (outcomes) reported during the trial; and the main conclusion of the study. The raw data (number of events in each group) were extracted for each outcome. The number of patients who experienced at least once any body system-related AE (e.g., nervous system, gastrointestinal system), as well as specific AEs within each body system (e.g., headache, abdominal pain), were extracted. Intention-to-treat (ITT) data were only used when reported or supplied by the study authors or sponsor.

Assessment of Risk of Bias in Included Studies {#Sec6}
----------------------------------------------

Two review team members (GH and AG) independently assessed the risk of bias in each study, using the Cochrane Collaboration's tool for risk of bias assessment \[[@CR23]\]. The following characteristics were evaluated:*Random sequence generation* We assessed whether the allocation sequence was adequately generated.*Allocation concealment* We assessed the method used to conceal the allocation sequence, evaluating whether the intervention allocation could have been foreseen in advance.*Blinding of participants and personnel* We assessed the method used to blind study participants and personnel from knowledge of which intervention a participant received and whether the intended blinding was effective.*Blinding of outcome assessment* We assessed the method used to blind outcome assessors from knowledge of which intervention a participant received and whether the intended blinding was effective.*Incomplete outcome data* We assessed whether participants' exclusions, attrition, and incomplete outcome data were adequately addressed in the paper.*Selective outcomes reporting* We checked whether there was evidence of selective reporting of AEs.

Each item was categorized as having "low" or "high" risk of bias when sufficient information was provided in the manuscript to judge the risk of bias; otherwise, the risk was classed as "unclear." Disagreements were solved by discussion between the two reviewers during a consensus meeting and, when necessary, another member of the review team (VR) was involved for final decision.

Outcomes of Interest {#Sec7}
--------------------

The main system organ classes (SOCs) that are likely to be affected by the use of various SYSADOAs in the treatment of OA were explored in this meta-analysis. The primary outcomes of interest were Medical Dictionary for Regulatory Activities (MedDRA) SOC-related AEs: gastrointestinal, vascular, cardiac, nervous system, skin and subcutaneous tissue, musculoskeletal and connective tissue (MSCT), renal and urinary, and overall severe and serious AEs. Secondary outcomes were withdrawals due to AEs (i.e., the number of participants who stopped the treatment because of an AE) and total AEs (i.e., the number of patients who experienced any AE at least once).

Data Analysis {#Sec8}
-------------

Analyses were performed using STATA 14.2 software. We described harms associated with the treatment as odds ratios (OR) with 95% CIs. We computed an overall effect size for each primary or secondary outcome (AE). Anticipating substantial variability among trial results (i.e., the inter-study variability), we assumed heterogeneity in the occurrence of the AEs, so we planned to use random-effects models for the meta-analyses. We estimated the overall effects and heterogeneity using the DerSimonian and Laird random-effects model \[[@CR25]\]. As this method provides biased estimates of the between-study variance with sparse events \[[@CR26], [@CR27]\], we also performed the meta-analyses using the restricted maximum likelihood (REML) method \[[@CR28]\]. Indeed, we planned in the protocol to use specific methods for rare events analysis if necessary. However, we reported only the results from the DerSimonian and Laird random-effects model, as we found no difference in the effects computed by the two methods. We preferred to report the results obtained with the DerSimonian and Laird method (which uses a correction factor) because it allows for displaying studies with null events on the forest plot, even if those with null event in both the intervention and the control groups are excluded from the overall effect size computation. Conversely, with the REML method, these studies are not displayed on the forest plot. Additionally, the STATA command, which performs the meta-analysis based on the REML method (metaan) has no option for displaying subgroups on the same graphic, unlike the DerSimonian and Laird method command (metan), which has this option ("by").

We tested heterogeneity using Cochran's *Q* test. As we performed a random-effects meta-analysis, we used the Tau^2^ estimate as the measure of the between-study variance. The *I*^2^ statistic was used to quantify heterogeneity, measuring the percentage of total variation across studies due to heterogeneity \[[@CR29]\]. In the case of substantial heterogeneity (*I*^2^ \> 50%) \[[@CR30]\], we prespecified to undertake subgroup analyses, stratifying the analyses according to participants' age in the intervention group, duration of OA complaint, location of OA (knee, hand, hip), number of joints involved, drug dose, duration of treatment, use of bioavailability enhancer, treatment regimen (single use vs. combination), industry involvement (sponsored vs. non-sponsored), nature of the product (pharmaceutical grade vs. food supplement), and risk of bias (e.g., studies with low risk of bias vs. all other studies).

Funnel plot asymmetry was assessed for publication bias by visual inspection and using the test proposed by Harbord et al. \[[@CR31]\], which is more suitable for dichotomous outcomes with effects sizes measured as ORs \[[@CR32]\] than the classical Egger's test \[[@CR33]\]. In the end, we assessed the certainty of each piece of evidence based on the GRADE approach \[[@CR34]\] and prepared summary of findings tables using the GRADEpro online software \[[@CR35]\].

Additional Analysis {#Sec9}
-------------------

We performed additional post-hoc meta-analyses, in parallel with the main meta-analysis including the studies responding to our pre-defined eligibility criteria. Studies allowing concomitant anti-OA medications, which were excluded based on our eligibility criteria, as well as all studies with or without concomitant anti-OA medications, were considered separately in parallel to the primary meta-analysis. These parallel analyses were conducted according to the same principles described in the data analysis section for the main meta-analysis. However, instead of depicting the results of the parallel analyses in separate forest plots, we prefer to show all the analyses for each outcome on the same figure for ease of comparison. Therefore, considering the rationale of this safety meta-analysis (the exclusion of studies with other anti-OA medication allowed), the parallel analyses on one single forest plot are not to be considered subgroup analyses as for a classical meta-analysis.

Results {#Sec10}
=======

Initial Study Selection and Characteristics {#Sec11}
-------------------------------------------

Database searches initially identified 3815 records; after exclusions (Fig. [1](#Fig1){ref-type="fig"}), 157 articles were assessed for eligibility. Of these, 132 studies were excluded for various reasons according to the predefined eligibility criteria (Fig. [1](#Fig1){ref-type="fig"}). In total, 25 papers were included in the qualitative synthesis according to our prespecified selection criteria, and 13 studies on various SYSADOAs with adequate data were ultimately included in the meta-analysis \[[@CR36]--[@CR60]\]. These studies that met our selection criteria included no concomitant anti-OA medication (in accordance with the protocol).Fig. 1Flow chart of the study. *OA* osteoarthritis

Table [1](#Tab1){ref-type="table"} presents the characteristics of all the studies included through the systematic review process, according to the predefined selection criteria (those ultimately included in the quantitative synthesis---meta-analysis---are highlighted). The large majority of the studies were in patients with knee OA, with only one including patients with hand OA, one including patients with temporomandibular joint (TMJ) OA, and one involving patients with OA of any joint. In most of the studies, treatment durations varied between 12 and 26 weeks, with the shortest being 4 weeks and the longest 156 weeks.Table 1Characteristics of the studies included in the systematic review process according to the prespecified selection criteria (without concomitant osteoarthritis medication). Studies are grouped by drug; those studies included in the quantitative synthesis are highlighted in bold typeStudyOA locationTreated groups/participant age^a^Compound nature: Pharmaceutical grade or food supplement (manufacturer)DoseTreatment duration (weeks)Data provided in article (type of AE/% of pts considered)Published data usable for MA? (yes/no)Full data provided by author/sponsor? (information source)*Glucosamine sulfate* ^b^**Cahlin and Dahlstrom** \[[@CR38]\]TMJFemale\
Active 61.0 ± 16.0\
Placebo 58.0 ± 9.0Manufactured by hospital pharmacy without industrial involvement400 mg × 3 capsules OD6 wkOnly GI AEs reportedNoYes (author)Chopra et al. \[[@CR39]\]KneeActive 54.2 ± 8.1\
Placebo 54.0 ± 7.7NATwo 250 mg capsules BID16 wkPer SOC frequencies NPNoAuthor contacted: no response**Esfandiari et al.** \[[@CR41]\]AnyActive 60.6 ± 11.0\
Placebo 58.8 ± 11.5Pharmaceutical grade (Avicenna Laboratories Inc., Tehran, Iran)750 mg TID13 wkFocus on IOP frequenciesNoYes (author)**Frestedt et al.** \[[@CR42]\]KneeActive 59.2 ± 8.3\
Placebo 58.9 ± 7.4Food supplement (Pharmachem Labs, NJ, USA)3 capsules TID (167 mg D-GS potassium salt + 267 mg maltodextrin)12 wkAll TEAEs seem to have been reported but only per SOC frequenciesYesAuthor contacted: no response**Noack et al.** \[[@CR49]\]KneeActive 55.0 ± 14.0\
Placebo 55.0 ± 15.0Pharmaceutical grade (Opfermann Arzneimittel GmbH, D-5276 Wiehl, Germany)2 tablets TID (GS 1500 mg/d)4 wkNot stated whether all AEs reported but per SOC data providedYesYes (author)**Pavelka et al.** \[[@CR50]\]KneeActive 61.2 ± 7.3\
Placebo 63.5 ± 6.9Pharmaceutical grade (Rottapharm group)1 × 1500 mg/d156 wkReporting per SOC frequencies but incomplete reporting of specific AEsYesNo (Rottapharm)Pujalte et al. \[[@CR53]\]KneeActive 58.8 ± 2.3\
Placebo 64.6 ± 2.3Pharmaceutical grade (Rotta Pharmaceuticals)2 capsules TID (250 mg each)6--8 wkSummary without detailsNoNo contact information foundUsha and Naidu^**c**^ \[[@CR59]\]KneeActive 52.0 ± 8.0\
Placebo 50.0 ± 9.0Nutraceutical (Healers Limited, Chennai, India)3 × 500 mg/d12 wkSummary without detailsNoClarifications from author insufficient for inclusion in MA*Glucosamine hydrochloride*Clegg et al. \[[@CR40]\]\
 a. GHKneeActive 58.6 ± 10.2\
Placebo 58.2 ± 9.8NA (various suppliers)GH 500 mg TID24 wkSummary without detailsNoAuthor contacted: no responseKwoh et al. \[[@CR46]\]KneeActive 52.2 ± 6.1\
Placebo 52.3 ± 6.7Food supplement (Cargill, Incorporated)Oral GH 1500 mg, in 16-ounce bottle of diet lemonade24 wkSummary without detailsNoAuthor contacted: no response*Chondroitin sulfate* ^b^**Bucsi and Poor** \[[@CR37]\]KneeActive 60.6 ± 9.6\
Placebo 59.4 ± 9.0Pharmaceutical grade (IBSA)800 mg/d26 wkSummary without detailsNoYes (IBSA)Clegg et al. \[[@CR40]\]\
 b. Chondroitin sulfateKneeActive 58.2 ± 10.0\
Placebo 58.2 ± 9.8NA (various suppliers)Sodium chondroitin sulfate 400 mg TID24 wkSummary without detailsNoAuthor contacted: no response**Gabay et al.** \[[@CR43]\]HandActive 63.9 ± 8.5\
Placebo 63.0 ± 7.2Pharmaceutical grade (IBSA)800 mg/d26 wkUnclear whether all AEs reported; per SOC frequencies NPNoYes (IBSA)Möller et al. \[[@CR48]\]KneeActive 58.6 ± 11.4\
Placebo 61.0 ± 10.4Pharmaceutical grade (Bioibérica, S.A., Barcelona, Spain)Daily CS 800 mg (1 × 2 capsules 400 mg each)13 wkSummary without detailsNoAuthor contacted: no response**Reginster** \[[@CR54]\]KneeActive 65.5 ± 8.0\
Placebo 64.9 ± 8.0Pharmaceutical grade (IBSA)1 × 800 mg OD26 wkSummary without detailsNoYes (IBSA)**Uebelhart et al.** \[[@CR57]\]KneeActive 60.0 ± 13.0\
Placebo 57.0 ± 11.0Pharmaceutical grade (IBSA)2 × 400 mg/d52 wkSummary without detailsNoYes (IBSA)**Uebelhart et al.** \[[@CR58]\]KneeActive 63.2 ± 9.1\
Placebo 63.7 ± 8.1Pharmaceutical grade (IBSA)800 mg chondroitin 4&6 sulfate; 1 sachet/d26 wk (intermittent administration from entry to mo 3 and between mo 6 and 9)Summary without detailsNoYes (IBSA)**Zegels et al.** \[[@CR60]\]\
 a. CS 1200\
 b. CS 3 × 400KneeActive a: 65.4 ± 10.4\
Active b: 65.3 ± 8.8\
Placebo 64.9 ± 10.6Pharmaceutical grade (IBSA)a. 1 oral gel sachet of CS 1200 mg/d\
b. 1 oral capsule of CS 400 mg TID13 wkSummary without detailsNoYes (IBSA)*Combined glucosamine sulfate/chondroitin sulfate*Roman-Blas et al. \[[@CR55]\]KneeActive 65.0 ± 8.0\
Placebo 67.0 ± 8.0Pharmaceutical grade (Tedec Meiji Farma)CS (1200 mg) plus GS (1500 mg) in a single oral daily dose26 wkSummary of treatment-related AEs; details NPNoYes (author)*Combined glucosamine hydrochloride/chondroitin sulfate*Clegg et al. \[[@CR40]\]\
 c. Combined GH + CSKneeActive 58.6 ± 10.6\
Placebo 58.2 ± 9.8NA (various suppliers)500 mg GH + 400 mg CS TID24 wkSummary without detailsNoAuthor contacted: no responseLugo et al. \[[@CR47]\]\
 a. Combined GH + CSKneeActive 52.6 ± 1.02\
Placebo 53.1 ± 1.02Nutraceuticals (GH: Wellable group, Shishi City, Fujian);\
CS, bovine-derived: Sioux Pharm, Sioux Center, IA, USA)Morning and evening doses delivered 750 mg GH + 600 mg CS each = 1500 mg GH + 1200 mg CS daily26 wkListing of all reported individual side effects but per SOC frequencies NPNoNo (author)*Hyaluronic acid*Kalman et al. \[[@CR45]\]KneeActive 57.7 ± 10.1\
Placebo 54.6 ± 7.7Dietary ingredient (Bioibérica, Barcelona, Spain)1 × 80 mg capsule/d8 wkNo. of AEs reported (summary)NoYes (author)*Collagen derivatives*Benito-Ruiz et al. \[[@CR36]\]KneeActive 59.4 ± 10.6\
Placebo 58.8 ± 11.4Food ingredient (Protein SA, Girona, Spain)10 g CH OD26 wkNo. of AEs reportedNoAuthor contacted: no responseJiang et al. \[[@CR44]\]KneeActive 60.9 ± 8.8\
Placebo 60.7 ± 6.2Food ingredient (Rousselot)Daily oral dose 8 g collagen peptides (Peptan^®^B 2000)26 wkAEs assessed but results NPNoClarifications from author insufficient for inclusion in MALugo et al. \[[@CR47]\]\
 b. Undenatured type II collagenKneeActive 53.5 ± 0.99\
Placebo 53.1 ± 1.02Nutraceuticals (Chick Cart Inc., Fort Smith, AR, USA)2 capsules × 20 mg each of UC-II totaling 40 mg = 1.2 mg UC-II26 wkListing of all reported individual side effects, but per SOC frequencies NPNoNo (author)Schauss et al. \[[@CR56]\]Hips and/or knee jointsActive 54.3 ± 8.69\
Placebo 54.5 ± 9.79Nutraceutical grade (BioCell Technology, Newport Beach, CA, USA)2 × 2 capsules (1 g) of BCC/d. Each capsule = 500 mg BCC (300 mg hydrolyzed collagen type II + other compounds)10 wkNo. AEs reportedNoAuthor contacted: no response*Diacerein* ^b^**Pavelka et al.** \[[@CR51]\]KneeActive 63.5 ± 8.39\
Placebo 63.8 ± 8.09Pharmaceutical grade (TRB Chemedica)50 mg diacerein capsules BID13 wkSummary of most common AEsNoYes (TRB Chemedica)**Pelletier et al.** \[[@CR52]\]\
 a. 50 mg/day\
 b. 100 mg/day\
 c. 150 mg/dayKneeActive a: 62.9 ± 8.4\
Active b: 64.2 ± 8.0\
Active c: 62.3 ± 10.2\
Placebo 64.5 ± 8.6Pharmaceutical grade (TRB Chemedica)a. 25 mg BID\
b. 50 mg BID\
c. 75 mg BID16 wkAEs that occurred in ≥ 5% of patients; but per SOC frequencies NPNoYes (TRB Chemedica)Where published data were adequate for inclusion in MA and full safety report also provided by the author/sponsor, we preferably used the full data obtained from the author/sponsor*AE* adverse event, *BCC* BioCell collagen, *BID* twice daily*, CS* chondroitin sulfate*, d* day, *GH* glucosamine hydrochloride, *GI* gastrointestinal, *IBSA* Institut Biochimique SA, *IOP* intraocular pressure, *MA* meta-analysis, *mo* month*, NA* not available, *NP* not provided*, OA* osteoarthritis, *OD* once daily, *pts* patients, *SOC* system organ class, *TEAE* treatment-emergent adverse event, *TID* three times daily, *TMJ* temporomandibular joint*, UC*-*II* undenatured type II collagen*, wk* week(s)^a^Data presented as mean ± standard deviation or median (P25--P75)^b^Drug with sufficient data for "individual MA"^c^Not stated in the paper whether glucosamine sulfate or glucosamine hydrochloride was used

Among the 25 articles initially selected for inclusion in this study (from trials without any concomitant anti-OA medication), only three had data usable, as published, for the meta-analysis; thus, the risk of selective outcome reporting bias was judged as "high" in \> 60% of these studies. Figures [2](#Fig2){ref-type="fig"}a and [3](#Fig3){ref-type="fig"}a include a summary of the risk of bias assessed for each of the studies included in the primary qualitative synthesis and the risk-of-bias items presented as percentages across all of them. Full data provided by study authors and/or sponsors ultimately enabled us to include 13 studies without any concomitant anti-OA medication in the meta-analyses: five were on GS, six on CS, and two on diacerein. All six studies on CS used the pharmaceutical-grade products manufactured by IBSA, Institut Biochimique SA. The two studies on diacerein used the pharmaceutical-grade product manufactured by TRB Chemedica. Only two of the five studies on GS used the pharmaceutical preparation of crystalline GS manufactured by Rottapharm.Fig. 2**a** Summary of risk of bias in studies without any concomitant anti-osteoarthritis medication (studies meeting prespecified selection criteria): review authors' judgements about each risk-of-bias item for each study included in the initial qualitative synthesis. **b** Risk-of-bias summary in studies with concomitant anti-osteoarthritis medication (studies included in the post hoc parallel qualitative synthesis): review authors' judgements about each risk-of-bias item for each study included in the parallel qualitative synthesis. *OA* osteoarthritisFig. 3**a** Risk-of-bias graph in studies without any concomitant anti-osteoarthritis medication: review authors' judgements about each risk-of-bias item presented as percentages across all studies included in the initial qualitative synthesis. **b** Risk-of-bias graph for studies with concomitant anti-osteoarthrits medication: review authors' judgements about each risk-of-bias item presented as percentages across all studies included in the parallel qualitative synthesis

Post-Hoc Study Selection and Characteristics {#Sec12}
--------------------------------------------

From the 132 studies previously excluded according to the protocol, 37 that permitted other pharmacologic OA treatments or that had no information about rescue or concomitant OA medications (Fig. [1](#Fig1){ref-type="fig"}) were included in a post hoc parallel qualitative synthesis, from which 18 studies with adequate data were ultimately included in post hoc parallel meta-analyses \[[@CR61]--[@CR97]\].

We a posteriori decided to consider these studies with other pharmacologic OA treatments in parallel analyses because we were surprised by their number compared with those with no concomitant pharmacologic OA treatment allowed. By doing so, we sought to compare the results from these two groups of studies, knowing that our main conclusions regarding the safety profile of each SYSADOA will primarily be based on the results of the analyses using the studies with no concomitant anti-OA medication (those responding to our prespecified selection criteria). Indeed, as this was a meta-analysis on safety, primarily excluding studies that allowed the use of concomitant anti-OA medications was crucial.

Table [2](#Tab2){ref-type="table"} presents the characteristics of the studies included in the post hoc parallel qualitative synthesis (those included in the parallel meta-analyses are highlighted). These studies largely involved patients with knee joint OA, as seen in the studies with no concomitant anti-OA medication. Conversely, the studies in the parallel qualitative synthesis included more long-term trials (12 studies \[32%\] with treatment duration ≥ 104 weeks) than the previous studies (4%). Oral nonsteroidal anti-inflammatory drugs (NSAIDs) were the most permitted concomitant medications.Table 2Characteristics of studies included in the parallel qualitative synthesis (trials with concomitant osteoarthritis medication allowed). Studies are grouped by drug; those studies included in the quantitative synthesis are highlighted in bold typeStudyOA locationTreated groups/participant age^a^Compound nature: Pharmaceutical grade or food supplement (manufacturer)DoseTreatment duration (weeks)Concomitant OA medication allowedData provided in article (type of AE/% of pts considered)Published data usable for MA? (yes/no)Full data provided by author/sponsor? (information source)*Glucosamine sulfate* ^b^**Cibere et al.** \[[@CR64]\]KneeMean (range)\
Active 64.0 (40.0--83.0)\
Placebo 65.0 (43.0--88.0)Nutritional supplement (VitaHealth, Canada)Variable: maximum 1500 mg/d26 wkNSAIDsSummary without detailsNoYes (author)Drovanti \[[@CR67]\]Any jointsMean ± SEM\
Active 61.3 ± 2.1\
Placebo 58.7 ± 2.5Pharmaceutical grade (Rotta Pharmaceuticals, Italy)2 × 250 mg TID (total 1.5 g)4 wkNo information about rescue medicationUnclear whether all AEs reported (seems to be a summary)NoNo (Rottapharm)**Fransen et al.** \[[@CR68]\]\
 a. GSKneeActive 61.2 ± 7.7\
Placebo 60.6 ± 8.1Dietary supplement (Supplied by Sanofi-Aventis Consumer Healthcare)2 × 753 mg OD104 wkOpioids, NSAIDsOnly AEs leading to withdrawal specifiedNoYes (author)**Giordano et al.** \[[@CR69]\]KneeActive 57.2 ± 7.2\
Placebo 58.09 ± 8.3Manufactured by Department of Pharmacology Giorgio Segre of the University of Siena1500 mg GS/d12 wkDiclofenac 150 mg, piroxicam 20 mg, naproxen 750 mg, aceclofenac 200 mgFrequency of most common AEs but per SOC frequencies NPNoYes (author)Herrero-Beaumont et al. \[[@CR70]\]KneeActive 63.4 ± 6.9\
Placebo 64.5 ± 7.2Pharmaceutical grade (Rottapharm)1500 mg OD26 wkIbuprofen max 4 × 400 mg/dSummary of AEs occurring in ≥ 3 pts in any group; per SOC frequencies NPNoNo (Rottapharm and author)Hughes and Carr \[[@CR71]\]KneeActive and placebo 62.28 ± 9.12Nutrient supplement (Health Perception UK)3 × 500 mg/d26 wkNSAIDsListed all reported individual side effects, but per SOC frequencies NPNoNo (author)Reginster et al. \[[@CR89]\]KneeActive 66.0 ± 8.1\
Placebo 65.5 ± 7.5Pharmaceutical grade (Rotta Research Group, Monza, Italy)1 × 1500 mg/d156 wkNSAIDs (diclofenac, piroxicam or proglumeta-cin)AEs with ≥ 5% frequency, but per SOC frequencies NPNoNo (Rottapharm)Rindone et al. \[[@CR90]\]KneeActive 63.0 ± 12.0\
Placebo 64.0 ± 11.0NA (Applehart Laboratories, Bedford, NH, USA)3 × 500 mg/d9 wkNSAIDs, hydrocodoneSummary without detailsNoNo (author)**Rozendaal et al.** \[[@CR91]\]HipActive 63.1 ± 9.5\
Placebo 63.7 ± 8.5Dietary supplement (Nutricia Manufacturing USA, Greenville, SC, USA)2 × 750 mg OD104 wkNSAIDs, tramadolAll TEAEs seem to have been reportedYesYes (author)Zenk \[[@CR97]\]NAActive 57 ± 13\
Placebo 58 ± 13Dietary supplement (NA)3 × 500 mg/d6 wkNaproxen 220 mg, ibuprofen 200 mgAll TEAEs seem to have been reported, but per SOC frequencies NPNoData sent by colleague of author but after completion of our analyses*Chondroitin sulfate* ^b^**Bourgeois et al.** \[[@CR63]\]\
 a. CS 1200 mg\
 b. CS 3 × 400 mgKneeActive a: 63.0 ± 11.0\
Active b: 63.0 ± 9.0\
Placebo 64.0 ± 8.0Pharmaceutical grade (IBSA)a. 1 oral gel sachet 1200 mg CS/d\
b. 3 capsules × 400 mg CS/d13 wkNSAIDsPer SOC frequencies of AEs reported; no details about specific AEsYesYes (Laboratoires Genevrier)**Fransen et al.** \[[@CR68]\]\
 b. CSKneeActive 59.5 ± 8.0\
Placebo 60.6 ± 8.1Dietary supplement (TSI Health Sciences, Australia)2 × 400 mg OD104 wkOpioids, NSAIDsOnly AEs leading to withdrawal specifiedNoYes (author)**Kahan et al.** \[[@CR72]\]KneeActive 62.9 ± 0.5\
Placebo 61.8 ± 0.5Pharmaceutical grade (Genévrier Laboratories, France & IBSA, Switzerland)800 mg OD104 wkNSAIDsSummary without detailsNoYes (IBSA)**Mathieu** \[[@CR78]\]KneeActive 62.5 ± 9.1\
Placebo 63.1 ± 10.7Pharmaceutical grade (Laboratoires Genévrier)1 × 800 mg/d104 wkNSAIDsOnly numbers of withdrawal due to AEs specifiedNoYes (Laboratoires Genevrier)Mazieres et al. \[[@CR79]\]Hip or kneeActive 64.5 ± 1.14\
Placebo 63.3 ± 1.07NA2 × 1000 mg/d13 wkNSAIDs (diclofenac, flurbiprofen, ibuprofen, indometacin, ketoprofen, naproxen, piroxicam, tenoxicam)All TEAEs seem to have been reported, but per SOC frequencies NPNoNo (Pierre Fabre)Mazieres et al. \[[@CR80]\]KneeActive 67.3 ± 7.8\
Placebo 66.9 ± 8.0NA2 × 500 mg/d13 wkNSAIDs (diclofenac, ketoprofen, naproxen)Summary without detailsNoNo (Pierre Fabre)Mazieres et al. \[[@CR81]\]KneeActive 66.0 ± 8.8\
Placebo 66.0 ± 7.7NA2 × 500 mg/d24 wkNSAIDsNumbers of AEs reported, not incidencesNoNo (Pierre Fabre)**Michel et al.** \[[@CR83]\]KneeActive 62.5 ± 9.1\
Placebo 63.1 ± 10.7Pharmaceutical grade (IBSA)1 × 800 mg/d104 wkNSAIDsFrequencies of ≥ 5% in one of two study groups provided for specific AEs; per SOC frequencies NPNoYes (IBSA)Railhac et al. \[[@CR88]\]KneeActive 63.6 ± 8.2\
Placebo 66.5 ± 8.1Pharmaceutical grade - Structum^®^2 × 500 mg/d48 wkNSAIDsSummary without detailsNoNo (Pierre Fabre)**Wildi et al.** \[[@CR96]\]KneeActive 59.7 ± 9.4\
Placebo 64.9 ± 9.5Pharmaceutical grade (Bioibérica S.A., Barcelona, Spain)2 × 400 mg/d26 wkNSAIDsNot specified whether all AEs reported; per SOC frequencies providedYesYes (author)*Combined glucosamine sulfate/chondroitin sulfate*Fransen et al. \[[@CR68]\]\
 a. Glucosamine --ChondroitinKneeActive 60.7 ± 8.4\
Placebo 60.6 ± 8.1Dietary supplements (GS: Sanofi-Aventis Consumer Healthcare;\
CS: TSI Health Sciences, Australia)1500 mg GS + 800 mg CS, OD104 wkOpioids, NSAIDsOnly AEs leading to withdrawal specifiedNoYes (author)*Combined glucosamine hydrochloride/chondroitin sulfate*Das et al. \[[@CR65]\]KneeActive 64.5 ± 9.8\
Placebo 66.0 ± 1.5Dietary supplements (Nutramax Laboratories Inc., Baltimore, MD, USA)1 × (500 mg GH + 400 mg CS + 76 mg manganese), BID26 wkNSAIDsAll TEAEs seem to have been reportedYesNo contact information found*Collagen derivatives*Kumar et al. \[[@CR73]\]\
 a. PCP vs. placebo PCP\
 b. BCP vs. placebo BCPKneeActive a: NA\
Placebo a: NA\
Active b: NA\
Placebo b: NANA (PCP: Nitta Gelatin Inc., Japan;\
BCP: Nitta Gelatin India Ltd)2 × 5 g/d13 wkAceclofenac sodium 100 mgSummary without detailsNoAuthor contacted: no responseMcAlindon et al. \[[@CR82]\]KneeActive 58.9 ± 8.0\
Placebo 60.3 ± 8.5NA -- Fortigel (Gelita AG)1 × 10 g CH/d48 wkAnalgesics or NSAIDsSummary without detailsNoYes (author)Stančík et al. \[[@CR94]\]KneeActive 53.4 ± 8.6\
Placebo 54.5 ± 8.1Dietary supplement -- Colafit^®^ (Dacom Pharma s.r.o., Czech Republic)1 × 8 mg pure lyophilized collagen type I in capsule13 wkNo information about concomitant medication useAll AEs seem to have been reportedYesCorresponding author unable to provide any information*Diacerein* ^b^**Dougados et al.** \[[@CR66]\]HipActive 63.0 ± 6.7\
Placebo 62.1 ± 7.0NA50 mg BID156 wkAnalgesics and/or NSAIDsMost commonly observed AEs; per SOC frequencies reportedYesYes (TRB Chemedica)**Lequesne et al.** \[[@CR74]\]Knee or hipMean\
Active 63.6\
Placebo 59.5NA50 mg BID26 wkNSAIDsSummary without detailsNoYes (TRB Chemedica)Nguyen et al. \[[@CR85]\]HipActive 63.0 ± 10.0\
Placebo 65.0 ± 11.0Pharmaceutical grade (Negma Pharma, Ltd., Buc, France)1 × 50 mg/d8 wkHypnotic drugs and/or muscle relaxantsFrequencies given for specific AEs, but not for body systemsNoData provided by TRB Chemedica, but reported as number of AEs and not frequencies. Not usable for M-A**Pham et al.** \[[@CR87]\]KneeActive 64.5 ± 7.8\
Placebo 64.9 ± 7.7NA50 mg BID52 wkNSAIDsMost commonly seen AEs reported. By SOC report for some SOCs, and only specific AEs for GIYesNo (Laboratoires NEGMA)**Shin et al.** \[[@CR92]\]HandActive 57.0 ± 7.0\
Placebo 58.6 ± 7.0Pharmaceutical grade (Myungmoon Pharmaceutical Co, Ltd, Seoul, Korea)1 × 50 mg/d12 wkNabumetone (unclear whether this was considered protocol violation)Frequencies of specific AEs, but per SOC frequencies NPNoYes (author)Vignon et al. \[[@CR95]\]HipActive NA\
Placebo NANA50 mg BID156 wkAnalgesics and/or NSAIDsSummary without detailsNoNo contact information found*Avocado soybean unsaponifiables (ASU)* ^b^**Appelboom et al.** \[[@CR61]\]\
 a. ASU 300 mg\
 b. ASU 600 mgKneeActive a: 63.4 ± 8.6\
Active b: 65.2 ± 8.5\
Placebo 66.3 ± 8.1Pharmaceutical grade (Pharmascience)a. 1 × 300 mg/d\
b. 1 × 600 mg/d13 wkAnalgesics and NSAIDsIncidence of side effects according to body systems; no details about specific AEsYesYes (Expanscience)**Blotman et al.** \[[@CR62]\]KneeActive 63.3 ± 7.6\
Placebo 65.1 ± 6.9Pharmaceutical grade (Pharmascience)1 × 300 mg capsule/d ASU13 wkNSAIDsFrequencies for specific AEs reported; per SOC frequencies NPNoYes (Expanscience)Lequesne et al. \[[@CR75]\]HipActive 63.3 ± 8.7\
Placebo 63.0 ± 8.8Pharmaceutical grade (Pharmascience)1 × 300 mg capsule ASU OD104 wkNSAIDsSummary without detailsNoNo (Expanscience)**Maheu et al.** \[[@CR76]\]Knee or hipActive 63.3 ± 7.6\
Placebo 65.1 ± 6.9Pharmaceutical grade (Pharmascience)1 × 300 mg capsule ASU OD26 wkNSAIDsIncidences of AEs reported for active but not placebo groupNoYes (Expanscience)**Maheu et al.** \[[@CR77]\]HipActive 61.6 ± 7.9\
Placebo 62.7 ± 8.0Pharmaceutical grade (Laboratoires Expanscience)1 × 300 mg capsule ASU OD156 wkAnalgesics and NSAIDsSummary without detailsNoYes (Expanscience)*Curcuma*Nakagawa et al. \[[@CR84]\]KneeActive 71.9 ± 5.3\
Placebo 66.1 ± 7.2Therapeutic food material (Theravalues, Tokyo, Japan)6 capsules of Theracurmin/d, containing curcumin 180 mg (BID)8 wkOral celecoxib and pain relief patchesIncomplete reporting (missing data for some events)NoYes (author)Panahi et al. \[[@CR86]\]KneeActive 57.3 ± 8.8\
Placebo 57.6 ± 9.1Dietary supplement (Sami Labs Ltd, Bangalore, India)C3 complex^®^, 3 × 500 mg/d6 wkNaproxenSummary without detailsNoNo (author)Srivastava et al. \[[@CR93]\]KneeActive 50.2 ± 8.1\
Placebo 50.3 ± 8.6NA (Himalaya Drug Company Bangalore, India)2 × 500 mg/d17 wkDiclofenac 50 mg/dayUnclear whether frequencies or numbers of AEs reportedNoNo (author)Where published data were adequate for inclusion in meta-analysis and full safety report also provided by the author/sponsor, we preferably used the full data obtained from the author/sponsor*AE* adverse event, *ASU* avocado soybean unsaponifiables, *BCP* collagen peptides isolated from bovine bone, *BID* twice daily, *CH* collagen hydrolysate, *CS* chondroitin sulfate*, d* day, *GI* gastrointestinal, *GS* glucosamine sulfate*, IBSA* Institut Biochimique SA, *MA* meta-analysis, *NA* not available, *NP* not provided, *NSAID* nonsteroidal anti-inflammatory drug, *OA* osteoarthritis, *OD* once daily, *PCP* collagen peptides isolated from pork skin, *pts* patients, *SEM* standard error of the mean, *SOC* system organ class, *TEAEs* treatment-emergent AEs, *wk* week^a^Mean ± standard deviation or median (P25--P75) unless otherwise indicated^b^Drug with sufficient data for 'individual MA

Harms-related data were relatively well reported in only eight studies, sufficient that they could be used for the analyses. Ultimately, in addition to the full data provided by study authors and/or sponsors, we could perform parallel post hoc meta-analyses for GS (four studies), CS (six studies), diacerein (four studies), and ASU (four studies). All the included studies on ASU used the pharmaceutical-grade proprietary product Piascledine^®^ (Expanscience). The raw data sent by study authors and/or sponsors resulted in a substantial decrease of the impact of selective outcome reporting bias in the studies included in the parallel meta-analyses. In fact, for 17 of the 18 studies included in these analyses, the data used were those sent by the study authors and/or sponsors. Originally, almost 70% of the studies included in the parallel qualitative synthesis were associated with a "high" risk of selective outcome reporting bias. Figures [2](#Fig2){ref-type="fig"}b and [3](#Fig3){ref-type="fig"}b include a summary of the risk of bias assessed for each study included in the parallel qualitative synthesis and the risk-of-bias items presented as percentages across all these studies.

Glucosamine Sulfate {#Sec13}
-------------------

For the primary outcomes, with or without concomitant anti-OA medications, there was no significant increase in the odds for any SOC-related disorders investigated (gastrointestinal, cardiac, vascular, nervous system, dermatological, MSCT, renal and urinary) with GS compared with placebo, as well as for severe and serious AEs (ESM-2).

Likewise, for the secondary outcomes, there was no significant increase in odds for total AEs reported with GS versus placebo (OR 0.96; 95% CI 0.66--1.41; *I*^2^ = 29.8%) (overall OR) (Fig. [4](#Fig4){ref-type="fig"}). In both studies with and those without concomitant anti-OA medications, as well as overall, there were no more withdrawals due to AEs with GS compared with placebo (ESM-2).Fig. 4Forest plot displaying the results of the meta-analyses comparing total adverse events with glucosamine sulfate versus placebo in patients with osteoarthritis: overall analysis and analyses of studies with and without concomitant anti-OA medication allowed. *CI* confidence interval, *OA* osteoarthritis

Chondroitin Sulfate {#Sec14}
-------------------

With or without concomitant anti-OA medications, there was no significant increase in the odds with CS versus placebo for any SOC-related disorders investigated or for severe and serious AEs and withdrawals due to AEs (ESM-2). Conversely, fewer AEs pertaining to the renal and urinary system were reported with CS than with placebo, whatever the group of studies considered; these findings reached statistical significance overall (OR 0.40; 95% CI 0.22--0.74) and in studies with concomitant anti-OA medications (OR 0.43; 95% CI 0.23--0.81) (ESM-2).

In studies with no concomitant OA medications allowed, patients receiving CS were significantly less likely to report AEs (total AEs) than were those receiving placebo (OR 0.70; 95% CI 0.51--0.98; *I*^2^ = 33.3%). The same trend was observed in studies with concomitant OA medications permitted, and overall, but this did not reach statistical significance (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Forest plot displaying the results of the meta-analyses comparing total adverse events with chondroitin sulfate versus placebo in patients with osteoarthritis: overall analysis and analyses of studies with and without concomitant anti-osteoarthritis medication allowed. *CI* confidence interval, *OA* osteoarthritis

Avocado Soybean Unsaponifiables {#Sec15}
-------------------------------

No statistically significant difference was found between ASU treatment and placebo for any SOC-related disorder investigated or for severe and serious AEs and withdrawals due to AEs (ESM-2).

All ASU studies allowed concomitant oral NSAIDs during the trials (Table [2](#Tab2){ref-type="table"}). Using data from these trials, ASU was no more likely than placebo to be associated with AEs (total AEs) (OR 1.09; 95% CI 0.81--1.46; *I*^2^ = 0%) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Forest plot displaying the result of the meta-analysis comparing total adverse events with avocado soybean unsaponifiables versus placebo in patients with osteoarthritis: analysis of studies with concomitant anti-osteoarthritis medications allowed. *CI* confidence interval, *OA* osteoarthritis

Diacerein {#Sec16}
---------

Significantly more gastrointestinal disorders were reported with diacerein than with placebo (OR 2.85; 95% CI 2.02--4.04; *I*^2^ = 62.8%), whether concomitant OA medications were allowed in the treatment protocol (OR 3.25; 95% CI 2.05--5.16; *I*^2^ = 51.3%) or not (OR 2.53; 95% CI 1.43--4.46; *I*^2^ = 73.6%) (Fig. [7](#Fig7){ref-type="fig"}). Diarrhea, abdominal pain, soft stools, and colitis were the most frequently reported gastrointestinal AEs.Fig. 7Forest plot displaying the results of the meta-analyses comparing gastrointestinal disorders with diacerein versus placebo in patients with osteoarthritis: overall analysis and analyses of studies with and without concomitant anti-osteoarthritis medication allowed. *CI* confidence interval, *OA* osteoarthritis

The odds of nervous system disorders (mostly dizziness) were significantly increased with diacerein but only among studies that did not allow concomitant pharmacologic OA treatment (OR 3.46; 95% CI 1.44--8.32; *I*^2^ = 0%) (Fig. [8](#Fig8){ref-type="fig"}).Fig. 8Forest plot displaying the results of the meta-analyses comparing nervous system disorders with diacerein versus placebo in patients with osteoarthritis: overall analysis and analyses of studies with and without concomitant anti-osteoarthritis medication allowed. *CI* confidence interval, *OA* osteoarthritis

Significantly increased odds of skin and subcutaneous tissue disorders were reported with diacerein in studies that allowed concomitant OA medications (OR 2.47; 95% CI 1.42--4.31; *I*^2^ = 0.0%), with eczema, rash, pruritus, and urticaria being the most reported specific events. There were also more skin and subcutaneous tissue disorders with diacerein than with placebo in studies that did not allow concomitant OA medications, but this did not reach statistical significance (Fig. [9](#Fig9){ref-type="fig"}).Fig. 9Forest plot displaying the results of the meta-analyses comparing dermatological adverse events with diacerein versus placebo in patients with osteoarthritis: overall analysis and analyses of studies with and without concomitant anti-osteoarthritis medication allowed. *CI* confidence interval, *OA* osteoarthritis

The odds of having renal and urinary disorders was significantly increased with diacerein versus placebo (OR 3.42; 95% CI 2.36--4.96; *I*^2^ = 17.0%), whether concomitant OA medications were used (OR 3.40; 95% CI 1.18--9.82; *I*^2^ = 68.2%) or not (OR 3.16; 95% CI 1.93--5.15; *I*^2^ = 0.0%) (Fig. [10](#Fig10){ref-type="fig"}). Urine discoloration and urinary tract infection were the most frequently reported specific AEs.Fig. 10Forest plot displaying the results of the meta-analyses comparing renal and urinary disorders with diacerein versus placebo in patients with osteoarthritis: overall analysis and analyses of studies with and without concomitant anti-osteoarthritis medication allowed. *CI* confidence interval, *OA* osteoarthritis

A reduced odds of MSCT disorders was observed with diacerein versus placebo when concomitant OA medications were not allowed during the trials (OR 0.53; 95% CI 0.35--0.82; *I*^2^ = 2.2%). This was not observed when concomitant OA medications were allowed (OR 1.19; 95% CI 0.82--1.73; *I*^2^ = 0%) (ESM-2).

Overall, and specifically in studies with or without concomitant OA medications, there were no increased odds of serious and severe AEs with diacerein compared with placebo (ESM-2).

Overall, diacerein was associated with significantly higher odds of any AE (total AEs), with or without concomitant OA treatment, compared with placebo (OR 2.22; 95% CI 1.58--3.13; *I*^2^ = 52.8%) (Fig. [11](#Fig11){ref-type="fig"}). In studies without any concomitant OA medications, diacerein was not associated with increased withdrawals due to AEs compared with placebo. However, more withdrawals due to AEs were seen with diacerein when concomitant anti-OA treatments were allowed (OR 3.18; 95% CI 1.85--5.47; *I*^2^ = 13.4%) (Fig. [12](#Fig12){ref-type="fig"}).Fig. 11Forest plot displaying the results of the meta-analyses comparing total adverse events with diacerein versus placebo in patients with osteoarthritis: overall analysis and analyses of studies with and without concomitant anti-osteoarthritis medication allowed. *CI* confidence interval, *OA* osteoarthritisFig. 12Forest plot displaying the results of the meta-analyses comparing withdrawals due to adverse events with diacerein versus placebo in patients with osteoarthritis: overall analysis and analyses of studies with and without concomitant anti-osteoarthritis medication allowed. *CI* confidence interval, *OA* osteoarthritis

No significant increase in serious or severe AEs was found with diacerein compared with placebo (ESM-2).

Assessment of Publication Bias {#Sec17}
------------------------------

We assessed funnel plot asymmetry for publication bias for each of the primary or secondary outcomes for GS, CS, ASU, and diacerein if there were sufficient data for each outcome. Only CS had sufficient studies for the Harbord's test for funnel plot asymmetry. Visual inspection of funnel plots (for all compounds) and formal test for funnel plot asymmetry with CS (Harbord's test) showed no evidence of publication bias, whatever the treatment. For each compound, funnel plots for "total AEs" are depicted in Fig. [13](#Fig13){ref-type="fig"}. All the other funnel plots are provided in ESM-3.Fig. 13Assessment of publication bias: funnel plots using data for the meta-analyses comparing total adverse events with **a** glucosamine sulfate, **b** chondroitin sulfate (Harbord's test: *p* = 0.54), **c** diacerein, and **d** avocado/soybean unsaponifiables, each versus placebo, in patients with osteoarthritis. *OA* osteoarthritis, *OR* odds ratio

GRADE Assessment of Findings {#Sec18}
----------------------------

Using the GRADE approach \[[@CR34]\], we assessed the certainty of evidence for each of the outcomes for GS, CS, ASU, and diacerein. Overall, for all of the outcomes considered for CS, ASU, and diacerein, the certainty of evidence was "high." For diacerein, this was downgraded to "moderate" for a few outcomes in studies with or without concomitant anti-OA medications (data not shown), because of the large CIs around the estimates. We found "moderate" certainty of evidence for severe and serious AEs with GS (overall) and for some other outcomes in studies with or without concomitant anti-OA medications (data not shown) because of wide CIs (imprecision) due to the low number of events (null events were reported in most of the included studies); for other outcomes, the certainty of evidence was "high" with GS. The detailed results for the main outcomes for each of these compounds are depicted in the summary of findings tables using data from "overall" meta-analyses (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}).Table 3Summary of findings for glucosamine sulfate vs. placebo in patients with osteoarthritisOutcomesNo. of participants (studies), follow-upCertainty of the evidence (GRADE)Overall relative effect (95% CI)Anticipated absolute effectsRisk with placeboRisk difference with glucosamine sulfateGastrointestinal AEs1351 (9 RCTs)⊕⊕⊕⊕\
HighOR 1.02 (0.74--1.40)150 per 10003 more per 1000\
(34 fewer to 48 more)Skin and subcutaneous tissue disorders1351 (9 RCTs)⊕⊕⊕⊕\
HighOR 0.80 (0.43--1.48)39 per 10007 fewer per 1000\
(22 fewer to 17 more)Renal and urinary disorders1149 (8 RCTs)⊕⊕⊕⊕\
HighNot estimable0 per 10000 fewer per 1000\
(0 fewer to 0 fewer)Severe AEs1351 (9 RCTs)⊕⊕⊕◯\
Moderate^a^OR 1.46 (0.26--8.13)12 per 10005 more per 1000\
(9 fewer to 77 more)Serious AEs1351 (9 RCTs)⊕⊕⊕◯\
Moderate^a^OR 2.04 (0.37--11.36)3 per 10003 more per 1000\
(2 fewer to 30 more)Withdrawals due to AEs1351 (9 RCTs)⊕⊕⊕⊕\
HighOR 0.86 (0.51--1.42)52 per 10007 fewer per 1000\
(25 fewer to 20 more)GRADE Working Group grades of evidence: *High certainty* we are very confident that the true effect lies close to that of the estimate of the effect; *Moderate certainty* we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; *Low certainty* our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect: *Very low certainty* we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effectThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)*AE* adverse event, *CI* confidence interval, *OR* odds ratio, *RCT* randomised controlled trial^a^Wide confidence interval because of low number of eventsTable 4Summary of findings for chondroitin sulfate vs. placebo in patients with osteoarthritisOutcomesNo. of participants (studies), follow-upCertainty of the evidence (GRADE)Overall relative effect (95% CI)Anticipated absolute effectsRisk with placeboRisk difference with chondroitin sulfateGastrointestinal AEs2877 (12 RCTs)⊕⊕⊕⊕\
HighOR 0.77 (0.59--1.00)159 per 100032 fewer per 1000\
(58 fewer to 0 fewer)Skin and subcutaneous tissue disorders2877 (12 RCTs)⊕⊕⊕⊕\
HighOR 1.07 (0.62--1.84)31 per 10002 more per 1000\
(11 fewer to 24 more)Renal and urinary disorders2877 (12 RCTs)⊕⊕⊕⊕\
HighOR 0.40 (0.22--0.74)26 per 100015 fewer per 1000\
(20 fewer to 7 fewer)Severe AEs2877 (12 RCTs)⊕⊕⊕⊕\
HighOR 0.82 (0.47--1.45)86 per 100014 fewer per 1000\
(44 fewer to 34 more)Serious AEs2877 (12 RCTs)⊕⊕⊕⊕\
HighOR 1.13 (0.84--1.52)75 per 10009 more per 1000\
(11 fewer to 35 more)Withdrawals due to AEs2877 (12 RCTs)⊕⊕⊕⊕\
HighOR 0.72 (0.44--1.16)56 per 100015 fewer per 1000\
(31 fewer to 8 more)GRADE Working Group grades of evidence: *High certainty* we are very confident that the true effect lies close to that of the estimate of the effect; *Moderate certainty* we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; *Low  certainty* our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect: *Very low certainty* we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effectThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)*AE* adverse event, *CI* confidence interval, *OR* odds ratio, *RCT* randomised controlled trialTable 5Summary of findings for diacerein vs. placebo in patients with osteoarthritisOutcomesNo. of participants\
(studies), follow-upCertainty of the evidence (GRADE)Overall relative effect (95% CI)Anticipated absolute effectsRisk with placeboRisk difference with diacereinGastrointestinal AEs1595 (6 RCTs)⊕⊕⊕⊕\
HighOR 2.85 (2.02--4.04)314 per 1000252 more per 1000\
(166 more to 335 more)Skin and subcutaneous tissue disorders1595 (6 RCTs)⊕⊕⊕⊕\
HighOR 2.18 (1.40--3.42)34 per 100037 more per 1000\
(13 more to 73 more)Renal and urinary disorders1595 (6 RCTs)⊕⊕⊕⊕\
HighOR 3.42 (2.36--4.96)70 per 1000135 more per 1000\
(81 more to 203 more)Severe AEs1088 (5 RCTs)⊕⊕⊕⊕\
HighOR 1.39 (0.78--2.48)40 per 100015 more per 1000\
(8 fewer to 53 more)Serious AEs1595 (6 RCTs)⊕⊕⊕⊕\
HighOR 0.95 (0.68--1.33)128 per 10006 fewer per 1000\
(37 fewer to 35 more)Withdrawals due to AEs1595 (6 RCTs)⊕⊕⊕⊕\
HighOR 1.85 (1.13--3.02)79 per 100058 more per 1000\
(9 more to 127 more)GRADE Working Group grades of evidence: *High certainty* we are very confident that the true effect lies close to that of the estimate of the effect; *Moderate certainty* we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; *Low certainty* our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; *Very low certainty* we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effectThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)*AE* adverse event, *CI* confidence interval, *OR* odds ratio, *RCT* randomised controlled trialTable 6Summary of findings for avocado/soybean unsaponifiables vs. placebo in patients with osteoarthritisOutcomesNo. of participants (studies), follow-upCertainty of evidence (GRADE)Relative effect (95% CI)Anticipated absolute effectsRisk with placeboRisk difference with ASUGastrointestinal AEs986 (4 RCTs)⊕⊕⊕⊕\
HighOR 0.91 (0.65--1.27)174 per 100013 fewer per 1000\
(54 fewer to 37 more)Skin and subcutaneous tissue disorders986 (4 RCTs)⊕⊕⊕⊕\
HighOR 0.91 (0.26--3.14)41 per 10004 fewer per 1000\
(30 fewer to 78 more)Renal and urinary disorders986 (4 RCTs)⊕⊕⊕⊕\
HighOR 1.12 (0.43--2.87)20 per 10002 more per 1000\
(11 fewer to 35 more)Severe AEs986 (4 RCTs)⊕⊕⊕⊕\
HighOR 0.89 (0.61--1.30)157 per 100015 fewer per 1000\
(55 fewer to 38 more)Serious AEs986 (4 RCTs)⊕⊕⊕⊕\
HighOR 1.31 (0.85--2.00)120 per 100031 more per 1000\
(16 fewer to 94 more)Withdrawals due to AEs986 (4 RCTs)⊕⊕⊕⊕\
HighOR 0.97 (0.55--1.70)48 per 10001 fewer per 1000\
(21 fewer to 31 more)GRADE Working Group grades of evidence: *High certainty* we are very confident that the true effect lies close to that of the estimate of the effect; *Moderate certainty* we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; *Low certainty* our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect; *Very low certainty* we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effectThe risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)*AE* adverse event, *CI* confidence interval, *OR* odds ratio, *RCT* randomised controlled trial

Discussion {#Sec19}
==========

In our analysis, we found no statistically significant increase in odds between either GS, CS, or ASU, each compared with placebo, for any of the SOC-related disorders investigated, including gastrointestinal, cardiac, vascular, nervous system, skin and subcutaneous tissue, MSCT, and disorders of the renal and urinary systems. In addition, we found no statistically significant difference in odds between either GS, CS, or ASU treatment and placebo for severe and serious AEs or for withdrawals due to AEs. Almost all of this new evidence was predominantly associated with "high" certainty; "moderate" certainty of evidence was found with two outcomes overall (only with GS) and with a few other outcomes with or without concomitant anti-OA medication (mainly with GS and diacerein) because of imprecision (wide CIs around the estimates).

Overall, this meta-analysis found no statistically significant increase in odds for total AEs reported with GS (with or without concomitant anti-OA -medication) versus placebo, and we found reduced odds for total AEs with CS compared with placebo, particularly in studies in which no concomitant OA medications were permitted. These findings agree with those of previous meta-analyses that have demonstrated GS and CS to be as safe as placebo, with no significant increase in odds for total AEs or dropouts due to AEs \[[@CR6], [@CR7], [@CR21]\]. In a network meta-analysis, Zeng et al. \[[@CR98]\] found no statistically significant increase in odds of specific AEs between GS and CS, each compared with placebo. The specific AEs investigated in that study were gastrointestinal, cardiovascular, central nervous system, infection, musculoskeletal and skin AEs.

A reduced odds of reporting renal and urinary disorders was found with CS compared with placebo in all the groups of studies analyzed, which was statistically significant overall (OR 0.40; 95% CI 0.22--0.74) and in studies with concomitant anti-OA medications (OR 0.43; 95% CI 0.23--0.81) (ESM-2). Likewise, as previously stated, the rate of total AEs was lower with CS than with placebo, and the difference in odds was statistically significant with studies with no concomitant anti-OA medication (OR 0.70; 95% CI 0.51--0.98). However, the data available from the studies included in these analyses did not allow us to identify the specific events reported more frequently in patients receiving placebo, particularly in the Kahan et al. \[[@CR72]\] study in which renal and urinary disorders were significantly more frequent in the placebo group (26 of 313 patients) compared with the CS group (9 of 309 patients). If these results are not due to chance, whether CS has potential for a protective effect against renal and urinary disorders deserves further investigation. The specific action of CS on the renal and urinary system needs to be identified, and the biological explanation of such an effect should also be clarified if this effect is confirmed by other studies.

With regards to ASU, all studies included in our analysis allowed concomitant oral NSAID treatment. However, ASU was not likely to be associated with more AEs than placebo. A recent Cochrane meta-analysis found no difference in risk of AEs with ASU versus placebo from data reported in five RCTs (*N* = 1050) (RR 1.04; 95% CI 0.97--1.12) \[[@CR22]\]. The analysis also found no difference between ASU and placebo in withdrawals due to AEs (one study, *N* = 398) (RR 1.14; 95% CI 0.73--1.80) or in serious AEs (one study, *N* = 398) (RR 1.22; 95% CI 0.94--1.59). In this Cochrane review, the analyses were only based on published and incomplete data. In our meta-analysis, we were able to include the raw data from the full safety reports of all the studies considered; these data were provided by the manufacturer of the compound (Table [2](#Tab2){ref-type="table"}). ASU is a complex mixture of many natural vegetable extracts taken from avocado and soybean oils, including fat-soluble vitamins, sterols, triterpene alcohols, and furan fatty acids \[[@CR99]\]; analysis of commercially available ASU supplements demonstrates variation in the sterol content \[[@CR99], [@CR100]\]. However, there is no concern about content variety of ASU in the current meta-analysis, as all the studies included through our systematic review process used the pharmaceutical-grade proprietary ASU product Piascledine^®^ (Expanscience) (Table [2](#Tab2){ref-type="table"}). Therefore, our findings regarding the safety profile of ASU may not apply to other preparations of ASU.

In a post-marketing safety analysis using data provided by the French spontaneous reporting system via the network of national pharmacovigilance centers, AEs affecting the skin, liver, gastrointestinal tract, and platelet aggregation (some being serious) have been reported with ASU \[[@CR101]\]. This raises concerns about the safety of ASU supplements, particularly in real life, and requires further investigation.

In our safety analysis, the odds of any AE with diacerein were significantly higher than with placebo, with or without concomitant OA treatment (OR 2.22; 95% CI 1.58--3.13). This was largely due to the increased odds of gastrointestinal AEs with diacerein versus placebo (OR 2.85; 95% CI 2.02--4.04), diarrhea, abdominal pain, soft stools, and colitis being frequently reported, and a considerable increase in the odds of renal and urinary disorders with diacerein (OR 3.42; 95% CI 2.36--4.96), urine discoloration being the most reported effect. These results were found in both studies with and without concomitant OA medications and are in agreement with a Cochrane meta-analysis, which found an increased risk of AEs with diacerein versus placebo: diarrhea (RR 3.52; 95% CI 2.42--5.11), urine discoloration (RR 13.01; 95% CI 5.96--28.40), and rash or pruritus (RR 1.99; 95% CI 0.94--4.23) \[[@CR20]\]. In a meta-analysis of RCTs, Bartels et al. \[[@CR5]\] also found a significantly increased risk of diarrhea with diacerein.

We also found significantly increased odds of dermatological disorders with diacerein versus placebo, overall (OR 2.18; 95% CI 1.40--3.42), and specifically eczema, rash, pruritus, and urticaria; these odds significantly increased when concomitant anti-OA treatment was allowed (OR 2.47; 95% CI 1.42--4.31) but not when there was no concomitant anti-OA medication (OR 1.74; 95% CI 0.82--3.70). Oral NSAIDs were the rescue or concomitant anti-OA medications allowed during the trials for both the diacerein and the placebo groups (Table [2](#Tab2){ref-type="table"}).

The odds of withdrawals due to AEs were significantly higher with diacerein than with placebo, overall (OR 1.85; 95% CI 1.13--3.02; *I*^2^ = 52.1%), and the increase was more important when concomitant anti-OA medications were allowed (OR 3.18; 95% CI 1.85--5.47; *I*^2^ = 13.4%), but no significant increase was found without concomitant anti-OA medications (OR 1.22; 95% CI 0.80--1.87; *I*^2^ = 0.0%). As shown by these results, there is moderate but statistically significant heterogeneity with the overall analysis (*I*^2^ = 52.1%, *p* = 0.04), which was eliminated when the studies with (*I*^2^ = 13.4%, *p* = 0.33) or without (*I*^2^ = 0.0%) concomitant anti-OA medications were considered separately. These results could suggest that the use of oral NSAIDs as rescue or concomitant medication might have played a role in the significantly increased number of withdrawals observed in patients receiving diacerein compared with those receiving placebo. However, we could not clinically explain this, as no drug interaction concern has been described with the coadministration of diacerein and NSAIDs \[[@CR102]\]. This warrants further investigation given that similar results have been obtained regarding skin and subcutaneous tissue disorders, with eczema, rash, pruritus, and urticaria being the most reported specific events.

Whatever the group of studies considered (overall, with or without concomitant anti-OA medications), there was no increase in severe or serious AEs with diacerein versus placebo. Unlike previous meta-analyses on the safety of diacerein in the treatment of OA that used only the published data, we were able to use the full safety reports data for five of six studies analyzed (Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}), which makes our estimates more precise than these previous estimates.

The safety of diacerein was called into question following case reports of severe diarrhea and rare cases of serious hepatotoxicity; however, the reported cases of liver disorders involved patients aged ≥ 65 years \[[@CR103]--[@CR105]\]. The European Medicines Agency (EMA) considered these safety issues and concluded that the benefit-risk balance of diacerein remained positive for hip and knee OA, particularly in patients aged \< 65 years \[[@CR106]\]. It is advised that patients start treatment on half the normal dose (i.e., 50 mg instead of 100 mg daily) and stop taking diacerein if diarrhea occurs. The limited number of studies on diacerein in our meta-analysis meant we were unable to perform a dose--response effect analysis through subgroup analyses. However, the results of individual studies, as depicted by Fig. [7](#Fig7){ref-type="fig"}, clearly indicated that gastrointestinal disorders were dose-dependent (detailed dose information in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}). Indeed, for the five studies for which we used the full safety report data, the individual ORs for gastrointestinal disorders increased with the dose of diacerein (Fig. [7](#Fig7){ref-type="fig"}), from 50 mg daily in the first arm (a) of the study by Pelletier et al. \[[@CR52]\] to 100 mg in the studies by Pavelka et al. \[[@CR51]\], Dougados et al. \[[@CR66]\], and Lequesne et al. \[[@CR74]\] and 150 mg in the third arm (c) of the study by Pelletier et al. \[[@CR52]\]. This potential dose--response effect may explain the heterogeneity observed, whatever the group of studies considered (Fig. [7](#Fig7){ref-type="fig"}).

Unlike the adverse effects associated with diacerein, a recent RCT in patients with inadequately controlled type 2 diabetes mellitus (T2DM) showed that diacerein improved glycemic control; this led the authors to conclude that diacerein would be an adequate adjunct treatment option for patients with OA and T2DM \[[@CR107]\]. Another recent RCT in patients with T2DM also concluded that diacerein could be a good treatment option in patients with T2DM with chronic kidney disease \[[@CR108]\].

Given the warnings about adverse liver reactions, the current status or history of liver disease should be considered when prescribing diacerein. However, further investigation regarding the adverse liver effects of diacerein in patients with OA is warranted. In fact, a very recent study in rats with induced abnormal liver function concluded that rhein (the metabolite of diacerein) had a hepatoprotective effect, suggesting its possible concomitant use in patients receiving methotrexate, a treatment associated with kidney and liver function abnormalities \[[@CR109]\].

Given the adverse effects associated with the use of diacerein, as shown by our analyses, and its positive effect on glycemic control, as reported by other studies, the usefulness of this compound in patients with OA should be assessed for each patient according to their individual characteristics, provided that its real benefit in terms of efficacy is proven.

Strengths {#Sec20}
---------

Our study has some specific strengths. First, we included only RCTs versus placebo, so the real effect was not underestimated. Second, we investigated many SOCs, not only "total AEs," "serious AEs," or "gastrointestinal AEs," as reported in many previous meta-analyses. Third, to avoid double counting of AEs, for each SOC, we considered the number of patients who experienced at least once any related AE. For total AEs, we considered the number of patients who experienced at least once any AE during the study.

Limitations {#Sec21}
-----------

Our study also had some limitations. Many of the identified studies that met the inclusion criteria did not provide AE data suitable for inclusion in the meta-analysis and the authors/sponsors did not provide us with the full safety data.

The current meta-analysis contains a unit-of-analysis error issue. However, the analyses on GS were not affected by this issue, and its impact on the results for the other compounds was very marginal. In fact, a unit-of-analysis problem arises in studies with multiple arms when the same group of participants is included twice in the same meta-analysis (e.g., if "dose 1 vs. placebo" and "dose 2 vs. placebo" are both included in the same meta-analysis, with the same original number of patients receiving placebo in both comparisons) \[[@CR23]\]. The Cochrane handbook proposes various approaches to include multiple groups from a single study in the same meta-analysis. For the current meta-analysis, one of these proposed methods was suitable, consisting of splitting the "shared" group into two or more smaller samples and including two or more comparisons. However, we decided not to apply this method, as we found that it only marginally and not significantly altered our results and did not modify our conclusions. Additionally, we wanted to obtain each comparison (active vs. placebo) with its real effect estimate and 95% CI as if we chose to select only one pair of interventions.

Conclusions {#Sec22}
===========

The SYSADOAs GS and CS can be considered safe treatments for patients with OA. The harmlessness of ASU must be confirmed in future studies without concomitant anti-OA medication, but current evidence seems to support its safety. Our findings regarding ASU are based on the proprietary product Piascledine^®^, as all the studies included in this systematic review used that preparation. Consequently, our conclusion regarding the safety of ASU may not apply to other preparations. Given the safety issues highlighted in this meta-analysis, the usefulness of diacerein for patients with OA should be considered, taking into account its dosage and patient characteristics. This is in accordance with the EMA recommendations. The safety profile for coadministration of diacerein and oral NSAIDs requires further investigation. Finally, these results, which are based on data from RCTs, must be confirmed with pharmacovigilance data.
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